Avantor (AVTR) Gets Boost From Trump's Pharma Tariffs

We recently published 11 Stocks Crushing Wall Street With Whopping Gains. Avantor Inc. (NYSE:AVTR) is one of the top performers on Tuesday.

Avantor Inc. (NYSE:AVTR) saw its share prices grow by 5.41 percent on Tuesday to close at $12.48 apiece as investor funds poured into stocks of pharmaceutical companies a day ahead of the imposition of levies on imported drugs.

On September 25, President Donald Trump announced the imposition of 100 percent tariff on imported branded or patented pharmaceutical products beginning October 1, but those building a manufacturing plant in the US will be spared from such.

In line with the new policy, the US government has conducted a national security investigation to determine tariffs on pharmaceuticals.

Avantor Inc. (NYSE:AVTR)—a US-based biotechnology and pharmaceutical company—stands to benefit from the import levies as it would markedly raise the prices of imported brands and make domestic alternatives more affordable and attractive to customers.

While we acknowledge the potential of AVTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.